Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D413874-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $319.90 | |
D413874-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,198.90 | |
D413874-50mg | 50mg | In stock | $1,799.90 | |
D413874-100mg | 100mg | In stock | $3,041.90 |
PKM Activators
Specifications & Purity | Moligand™, ≥98% |
---|---|
Biochemical and Physiological Mechanisms | DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ACTIVATOR |
Mechanism of action | Activator of pyruvate kinase M1/2 |
Product Description | Information DASA-58 DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator. Targets PKM2 In vitro DASA-58 inhibits LPS-induced Hif-1α and IL-1β, as well as the expression of a range of other Hif-1α-dependent genes in primary BMDMs, and also inhibits glycolysis and the accumulation of succinate in LPS-activated macrophages. In PC3 cells, DASA-58 impairs stromal-induced EMT program by restoring PK activity and abrogating the nuclear translocation of PKM2, as well as its association with HIF-1α. DASA-58 also dramatically reduces (~6-fold) CAFs-induced lung metastases formation in PC3 cells. In vivo DASA-58 (40 μM) affects EMT of prostate cancers and tumor dissemination in SCID mice. |
ALogP | 0.632 |
---|---|
HBD Count | 1 |
Rotatable Bond | 4 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline |
---|---|
INCHI | InChI=1S/C19H23N3O6S2/c20-15-3-1-4-16(13-15)29(23,24)21-7-2-8-22(10-9-21)30(25,26)17-5-6-18-19(14-17)28-12-11-27-18/h1,3-6,13-14H,2,7-12,20H2 |
InChi Key | GMHIOMMKSMSRLY-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCN(C1)S(=O)(=O)C2=CC=CC(=C2)N)S(=O)(=O)C3=CC4=C(C=C3)OCCO4 |
Isomeric SMILES | C1CN(CCN(C1)S(=O)(=O)C2=CC=CC(=C2)N)S(=O)(=O)C3=CC4=C(C=C3)OCCO4 |
PubChem CID | 44543605 |
Molecular Weight | 453.53 |
PubChem CID | 44543605 |
---|---|
CAS Registry No. | 1203494-49-8 |
ChEMBL Ligand | CHEMBL1089334 |
BindingDB Ligand | 50361557 |
RCSB PDB Ligand | 3SZ |
Enter Lot Number to search for COA:
Solubility | Solubility (25°C) In vitro DMSO: 91 mg/mL (200.64 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 91 |
DMSO(mM) Max Solubility | 200.6482482 |
Water(mg / mL) Max Solubility | <1 |
1. Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, Cantley LC, Israelsen WJ, Vander Heiden MG, Shen M et al.. (2011) 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.. Bioorg Med Chem Lett, 21 (21): (6322-7). [PMID:21958545] [10.1021/op500134e] |
2. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A et al.. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.. Nat Chem Biol, 8 (10): (839-47). [PMID:22922757] [10.1021/op500134e] |